NOTE THIS: ViroPharma has subsequently received an upfront payments of $16 million from Schering-Plough, and may receive additional monies associated milestones totaling up to an additional $65 million, and also royalties on sales of the product, if approved.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.